Long-Term Data Demonstrate Risankizumab Improves Psoriatic A

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Related Keywords

Melbourne , Victoria , Australia , , Health Assessment Questionnaire , American College Of Rheumatology , Emeritus Research , Classification Criteria , Psoriatic Arthritis , American College , Psoriasis Area , Severity Index , Health Assessment Questionnaire Disability Index ,